Failed to register as Favorite Page
Failed to cancel as Favorite Page
This page is already registered as a Favorite Page
You can't add your company to your favorites.
Latest update： 22/11/2017 02:13:37
Cheiron Japan Co., Ltd.
We research and develop chronic renal failure diets and other medical products.
Our company develops, researches, and sells medicines, medical equipment, and food for patients based on medical insight. Our Cheirox chronic renal failure diet was devised by a medical doctor, and has been favorably received in the medical field. Mr. Yasumi Yugari, former executive director of Ajinomoto, was appointed as our representative director in 2011, and our company has since conducted R&D and created original articles under his leadership. We will continue to facilitate commercialization of these projects. We possess patents for peritoneal dialysis fluid and a urination control unit, and international patents have already been granted in the US and Europe (EPC). Patent applications in China, Korea, and India are pending.
[Company strength] Our company appointed Mr. Yasumi Yugari, former executive director of Ajinomoto, as our new representative director in 2011. He has led our R&D activities to success, and created the original articles that we possess today. We intend to work harder to productize these items. [Business description] Our company researches, develops, and sells medicines, medical equipment, and food for patients based on medical insight. Our Cheirox chronic renal failure diet was devised by a medical doctor, and it is highly valued in the medical field. [Industry] Research and development [Representative's message] Our company possesses globally innovative and significant medicines, medical equipment, and food for patients that were independently developed by a medical doctor. We are constantly thinking in the medical field regarding what medicine can help improve society and which medical equipment can make patients happier. We hope to make use of J-GoodTech to introduce our products, and acquire potential licensing partners in Japan as well as overseas. [Company structure for market development/overseas expansion] We have introduced our self-developed medicines, medical equipment, and food for patients at exhibition booths at the academic meeting and general assembly of the Japanese Society for Dialysis Therapy. We have exhibited at the academic meeting and general assembly of the Japan Academy of Nephrology Nursing, and of the Japan Academy of Nursing Science’s nursing management division. We participated in the ISN NEXUS Kyoto 2010 Symposium. We have also participated in the annual academic meeting of the Japan Society of Metabolism and Clinical Nutrition, the Federation of Asian Nutrition Societies, and the New Value Creation Exhibition. We have already cultivated sales channels based on our business model of concluding exclusive sales agreements with domestic Japanese and overseas companies that want to sell our products. We have an established framework for providing our rare products based on medical insight. [Awards and media coverage] Our president received the Paul Lewis Award for the discovery of lysine biosynthesis (1965) and the Japan Society of Nutrition and Food Science Award (1981). [Intellectual property] Peritoneal Dialysis Fluid (Japanese Patent No. 4224117); Urination Control Unit (Japanese Patent No. 5745400). Note: Patents granted in the US and Europe (EPC); patent applications pending in China, Korea, and India.
This company is recommended by the following support organizations.
- Kanto Head Office, SMRJ
- Marketing Support Department, SMRJ